The company has an explicit strategy to use M&A and partnerships to enhance its commercial portfolio and clinical pipeline.
Filing excerpt
In addition, we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic areas through strategic collaborations, in-licensing and acquisitions.
What this signalsIntegration work after a deal often opens needs for new systems and services.
sec-10kacquisitionAnnouncedGet every 10-K signal for Gilead and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/8b723186-c681-41bd-a96c-80e011adb5ec returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.
{
"signal_id": "8b723186-c681-41bd-a96c-80e011adb5ec",
"signal_type": "sec-10k",
"signal_subtype": "acquisitionAnnounced",
"detected_at": "2026-03-03T05:50:03.57+00:00",
"company": {
"name": "Gilead",
"domain": "gilead.com"
},
"data": {
"detail": "The company has an explicit strategy to use M&A and partnerships to enhance its commercial portfolio and clinical pipeline. This indicates executive focus and budget allocation for deal-making, creating opportunities for M&A advisory, due diligence, and post-merger integration services.",
"metrics": {
"timeframe": "next_year"
},
"summary": "Gilead states intent to pursue acquisitions and in-licensing to grow portfolio.",
"excerpts": "In addition, we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic areas through strategic collaborations, in-licensing and acquisitions.",
"relevance": 0.7,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm",
"filing_date": "2026-02-24",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Integration needs coming",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/8b723186-c681-41bd-a96c-80e011adb5ec \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.